# Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding

> **NCT02158182** · PHASE4 · COMPLETED · sponsor: **Hospital General de Mexico** · enrollment: 88 (actual)

## Conditions studied

- Hepatic Encephalopathy

## Interventions

- **DRUG:** Lactulose
- **DRUG:** L-ornithine L-aspartate
- **DRUG:** Rifaximin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02158182
- **Lead sponsor:** Hospital General de Mexico
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2018-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02158182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02158182, "Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02158182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*